SEC Comment Letter 0000000000-24-005354 to Quantum Genesis AI Corp. (QTZM)
Quantum Genesis AI Corp.
Date: May 10, 2024 · CIK: 0001663038 · Accession: 0000000000-24-005354
AI Filing Summary & Sentiment
File numbers found in text: 024-12403
Letter
United States securities and exchange commission logo May 10, 2024 Naveen Krishnarao Kulkarni Chief Executive Officer and President Quantumzyme Corp. 15656 Bernardo Center Drive Suite 801 San Diego, CA 92127 Re:Quantumzyme Corp. Amendment No. 2 to Offering Statement on Form 1-A Filed April 29, 2024 File No. 024-12403 Dear Naveen Krishnarao Kulkarni: We have reviewed your amended offering statement and have the following comment(s). Please respond to this letter by amending your offering statement and providing the requested information. If you do not believe a comment applies to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response. After reviewing any amendment to your offering statement and the information you provide in response to this letter, we may have additional comments. Unless we note otherwise, any references to prior comments are to comments in our April 18, 2024 letter. Amendment 2 to Offering Statement on Form 1A submitted April 29, 2024 Description of Business The Quantumzyme Solution, page 25 1.We note your revised disclosure in response to comment 4. I appears from the revised disclosure that, thus far, you have engineered one product, an enzyme that you believe could be used in the manufacture of Ibuprofen, as disclosed on page 21. If so, please revise to clarify what further steps would be needed for you to commercialize this product. For example, does it require FDA approval, and if so, disclose what type of FDA review would be required. To the extent you have begun any other programs and they are currently material to your business, disclose at what phase of development you have reached with those programs. Finally, we note that you conduct your research and development activities at offsite facilities. Revise to clarify whether you lease or own those facilities and any agreements you have for their use.
FirstName LastNameNaveen Krishnarao Kulkarni Comapany NameQuantumzyme Corp. May 10, 2024 Page 2 FirstName LastName Naveen Krishnarao Kulkarni Quantumzyme Corp. May 10, 2024 Page 2 Please contact Robert Augustin at 202-551-8483 or Abby Adams at 202-551-6902 with any other questions. Sincerely, Division of Corporation Finance Office of Industrial Applications and Services
Show Raw Text
United States securities and exchange commission logo
May 10, 2024
Naveen Krishnarao Kulkarni
Chief Executive Officer and President
Quantumzyme Corp.
15656 Bernardo Center Drive
Suite 801
San Diego, CA 92127
Re:Quantumzyme Corp.
Amendment No. 2 to Offering Statement on Form 1-A
Filed April 29, 2024
File No. 024-12403
Dear Naveen Krishnarao Kulkarni:
We have reviewed your amended offering statement and have the following comment(s).
Please respond to this letter by amending your offering statement and providing the
requested information. If you do not believe a comment applies to your facts and circumstances
or do not believe an amendment is appropriate, please tell us why in your response.
After reviewing any amendment to your offering statement and the information you
provide in response to this letter, we may have additional comments. Unless we note otherwise,
any references to prior comments are to comments in our April 18, 2024 letter.
Amendment 2 to Offering Statement on Form 1A submitted April 29, 2024
Description of Business
The Quantumzyme Solution, page 25
1.We note your revised disclosure in response to comment 4. I appears from the revised
disclosure that, thus far, you have engineered one product, an enzyme that you believe
could be used in the manufacture of Ibuprofen, as disclosed on page 21. If so, please
revise to clarify what further steps would be needed for you to commercialize this
product. For example, does it require FDA approval, and if so, disclose what type of FDA
review would be required. To the extent you have begun any other programs and they are
currently material to your business, disclose at what phase of development you have
reached with those programs. Finally, we note that you conduct your research and
development activities at offsite facilities. Revise to clarify whether you lease or own
those facilities and any agreements you have for their use.
FirstName LastNameNaveen Krishnarao Kulkarni
Comapany NameQuantumzyme Corp.
May 10, 2024 Page 2
FirstName LastName
Naveen Krishnarao Kulkarni
Quantumzyme Corp.
May 10, 2024
Page 2
Please contact Robert Augustin at 202-551-8483 or Abby Adams at 202-551-6902 with
any other questions.
Sincerely,
Division of Corporation Finance
Office of Industrial Applications and
Services